BAYER AG NA O.N.
Commented by Armin Schulz on March 11th, 2026 | 07:20 CET
Three trends, one goal: How Bayer, MustGrow Biologics, and BASF are turning the agricultural revolution into a profit opportunity
Three trends are currently driving the global agricultural economy: skyrocketing fertilizer prices, regulatory pressure to preserve biodiversity, and the insatiable hunger of a growing population. As farmers navigate between existential fears and the pressure to go green, a billion-dollar transformation of industry is looming. Old chemistry is reaching its limits, while demand for biological alternatives and precision technologies is reaching an all-time high. Amid this tension between volatility and opportunity, the future of plant production is being reshaped. We take a look at how Bayer, MustGrow Biologics, and BASF are driving this transformation and could benefit from it.
Read
Commented by Fabian Lorenz on March 6th, 2026 | 07:20 CET
SHORT SQUEEZE at Gerresheimer? Will Bayer and MustGrow soon grow together?
While the stock market digests the Iran war and rising energy prices, Gerresheimer's share price is suddenly rising noticeably. There is no news. Is a short squeeze possible? Short sellers had even expanded their positions recently. Bayer does not (yet) hold a stake in MustGrow. However, the Leverkusen-based company has acquired a license to distribute the innovative agricultural products and is investing in their approval. This could enable MustGrow shares to make the leap from hidden gem to high flyer. Management has recently expressed optimism. The stock appears to be undervalued. After the sharp setback in recent weeks, analysts see upside potential for Bayer again. However, shareholders should not expect much in terms of revenue and profit growth in the current year. Cash flow is even expected to be significantly negative.
Read
Commented by Mario Hose on March 2nd, 2026 | 08:00 CET
Feeding a Growing World: Bayer, K+S, and MustGrow Biologics! Mustard, as a biological innovation, is transforming the agriculture of tomorrow!
Global agriculture faces mounting structural pressure. More than 8 billion people live on Earth today, and every person needs food every day. But the fields where we can grow food are getting smaller. Traditional methods of agriculture are losing acceptance, as synthetic fertilizers and chemical crop protection agents face stricter environmental oversight worldwide. That is why companies such as MustGrow Biologics, Bayer, and K+S are becoming increasingly important. These companies are working on a new type of agriculture. They are attempting to strike a balance: they aim to ensure good harvests while also protecting nature. The smaller innovator, MustGrow Biologics, exemplifies the shift toward effective biological alternatives in modern agriculture.
Read
Commented by Fabian Lorenz on March 2nd, 2026 | 07:40 CET
First Majestic Silver hits an all-time high! Could Silver Viper Minerals be next? Resistance at Bayer!
The silver rally is far from over, as the price of the precious metal has stabilized at a high level of USD 90 per ounce, enabling the industry to generate high revenues. First Majestic is an impressive example, with investors celebrating record figures that pushed the stock to a new all-time high last week. Similarly, Silver Viper Minerals is drawing attention, offering clear growth targets and fueling takeover speculation. The CEO made a convincing case at an investor conference last week, outlining the Canadians’ 2026 motto: “drill, drill, drill.” At the same time, the company aims to grow through acquisitions, likely ensuring an exciting news flow. Meanwhile, at Bayer, the focus is back on glyphosate. Recent optimism about an end to the saga had driven the stock higher, but now, resistance is emerging.
Read
Commented by Mario Hose on February 27th, 2026 | 07:05 CET
Revolution in cancer therapy: Vidac Pharma attacks the cancer throne of the big players! Why the smaller competitor could steal the show from giants like Bayer and BioNTech!
The world of biotechnology and pharmaceuticals is currently in turmoil, as technological breakthroughs and strategic realignments promise an exciting future for investors. The focus is particularly on Vidac Pharma, an innovative company that wants to revolutionize the fight against cancer with a completely new approach to oncology and is currently celebrating one milestone after another. While Vidac Pharma shines with impressive clinical progress and strong internal backing from its main shareholder, Dr. Max Herzberg, industry giant Bayer has recently struggled with the late effects of the Monsanto acquisition, but is now increasingly being touted as an exciting candidate for a split or takeover by financial investors. At the same time, BioNTech remains synonymous with cutting-edge mRNA technology, with the market eagerly awaiting the next phase after the pandemic. In this dynamic environment, Vidac Pharma is emerging as a particularly bright star in the biopharmaceutical sky, causing a sensation with its unique method of specifically normalizing the metabolism of cancer cells.
Read
Commented by Armin Schulz on February 24th, 2026 | 07:15 CET
MustGrow Biologics and its partnership with Bayer: Why the stock is only just getting started
Global agriculture is facing a paradox. It needs to feed more people, but with fewer chemical inputs. Worldwide, 460 pesticides are now banned or restricted across 162 countries. The era of synthetic active ingredients is coming to an end – but what comes next? A Canadian company believes it has found the answer. It grows in the field, is spicy and yellow: mustard. MustGrow Biologics has developed a technology that uses the natural defenses of the mustard plant to remediate soils and increase yields. What sounds like a niche idea could turn out to be one of the most exciting investments in the agricultural sector.
Read
Commented by Nico Popp on February 20th, 2026 | 07:25 CET
Agricultural revolution breaks the billion-dollar barrier: Why MustGrow Biologics, Bayer, and Bioceres Crop Solutions are ending the era of chemicals
The agricultural industry is currently transitioning from toxic chemicals to high-performance biologics. In this market environment, various players are positioning themselves with complementary strategies to capture the gigantic market for sustainable crop protection, which is expected to generate billions of dollars in revenue in the future. The ongoing deterioration of farmland and increasingly restrictive regulations are forcing farmers and corporations alike to rethink their approaches. It is no longer just about purely ecological ideals, but about food for humanity. Established agricultural giants and innovative technology companies are working feverishly to secure yields without further depleting nature. In this race, clear winners are emerging who are laying the foundation for the agriculture of the future and offering investors unprecedented opportunities. MustGrow Biologics is an exciting candidate.
Read
Commented by Armin Schulz on February 17th, 2026 | 08:10 CET
Cancer Research as a Growth Driver: How Bayer, Vidac Pharma, and Pfizer can enrich your portfolio
Oncology will be put to the test for the pharmaceutical industry in 2026. Never before have so many highly specialized active ingredients been on the verge of market launch at the same time. While checkpoint inhibitors and targeted therapies are revolutionizing treatment, business models are shifting from broad-based approaches to precision medicine. But the reality remains complex: between medical advances, narrow patient groups, and pressure on prices, companies need to readjust. Current developments at Bayer, Vidac Pharma, and Pfizer show how three players with different strategies are responding to this change.
Read
Commented by Fabian Lorenz on February 10th, 2026 | 07:00 CET
Rheinmetall, Bayer, Avrupa Minerals: Stocks for Europe's independence in defense, pharmaceuticals, and raw materials!
Europe is working feverishly to achieve independence. This applies, among other things, to defense, raw materials, and medicines. Investors can profit from these three stocks. Avrupa Minerals is developing raw material projects in Finland, Portugal, and other countries, skillfully diversifying to reduce risks. The stock is still largely unknown, but this is likely to change soon. Rheinmetall is a basic investment, although there was a noticeable drop in its share price last week. Are expectations too high? At the beginning of 2025, there were hardly any expectations for Bayer. This made the comeback of the company and its stock all the more spectacular. Recently, positive study results have once again caused excitement. The next blockbuster is in the pipeline.
Read
Commented by Fabian Lorenz on February 9th, 2026 | 07:30 CET
Bayer shares in the fast lane! Partner MustGrow Biologics facing revaluation!
For Bayer, things are currently going extremely well. The group is bringing its problem areas under control while reporting tangible progress in its pharmaceutical business. In the shadow of this, the company has secured the license for a new biologically safe product platform for fertilizers. Its partner in this venture is MustGrow Biologics. The company is on the verge of transitioning from research to commercialization, with management planning a market launch later this year. Production capacities are already being expanded in Asia. Against this backdrop, MustGrow shares appear poised for a revaluation - and the company is increasingly emerging as a potential takeover candidate.
Read